MedTrace Logo

Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients

NCT01820767 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2018-08-24

No results posted yet for this study

Summary

Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of inflammatory and oxidative stress parameters.

Conditions

Interventions

DRUG

Paricalcitol

Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.

DRUG

Paricalcitol, atorvastatin

Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks. Atorvastatin: 20 mg/day oral (1 take) during 12 weeks.

DRUG

Atorvastatin

Atorvastatin: 20 mg/day oral (1 take) during 12 weeks

Sponsors & Collaborators

  • Ricardo Mouzo Mirco

    lead OTHER

Principal Investigators

  • Ricardo Mouzo Mirco, MD · Hospital El Bierzo, Fuentesnuevas Ponferrada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-10-31
Completion
2014-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01820767 on ClinicalTrials.gov